1. Home
  2. SRRK vs TMDX Comparison

SRRK vs TMDX Comparison

Compare SRRK & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

N/A

Current Price

$42.47

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

N/A

Current Price

$110.10

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRRK
TMDX
Founded
2012
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.6B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
SRRK
TMDX
Price
$42.47
$110.10
Analyst Decision
Strong Buy
Buy
Analyst Count
11
9
Target Price
$55.40
$154.00
AVG Volume (30 Days)
1.3M
927.9K
Earning Date
03-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
382.18
EPS
N/A
4.87
Revenue
N/A
$605,494,000.00
Revenue This Year
N/A
$24.12
Revenue Next Year
$449.79
$18.69
P/E Ratio
N/A
$23.31
Revenue Growth
N/A
37.13
52 Week Low
$22.71
$62.42
52 Week High
$49.82
$156.00

Technical Indicators

Market Signals
Indicator
SRRK
TMDX
Relative Strength Index (RSI) 45.45 30.85
Support Level $41.54 $109.43
Resistance Level $42.54 $131.86
Average True Range (ATR) 2.40 6.46
MACD 0.05 -2.33
Stochastic Oscillator 38.83 3.41

Price Performance

Historical Comparison
SRRK
TMDX

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: